Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ImmuCellICCC +4.00%54 EV-to-EBITDA is 26.30 as of Aug. 20, 2026, which is 6% above its 10-year median of 24.91. GuruFocus rates ICCC with a GF Score™ of 54/100 and a GF Value™ of $6.91 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 402 Biotechnology companies, ImmuCell ranks worse than 66.92% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, ImmuCell's enterprise value is $95.59 Mil.
ImmuCell's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $3.64 Mil. Therefore, ImmuCell's EV-to-EBITDA for today is 26.30.
The historical rank and industry rank for ImmuCell's EV-to-EBITDA or its related term are showing as below:
ICCC'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -264.83 Med: 24.91 Max: 587.72
Current: 26.3
During the past 13 years, the highest EV-to-EBITDA of ImmuCell was 587.72. The lowest was -264.83. And the median was 24.91.
ICCC's EV-to-EBITDA is ranked worse than 66.92% of 402
companies
in the Biotechnology industry
Industry Median: 14.41
vs ICCC: 26.30
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
ImmuCell's share price for today is $10.13.
ImmuCell's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.080.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for ImmuCell's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, ImmuCell's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ImmuCell EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ImmuCell's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where ImmuCell's EV-to-EBITDA falls into.
ImmuCell's current Enterprise Value is $95.59 Mil.
ImmuCell's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.64 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ImmuCell (ICCC) has a EV-to-EBITDA of 26.30 as of Aug. 20, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on ImmuCell. This is near median its historical median of 24.91. According to the industry distribution chart, ImmuCell ranks #269 out of 402 companies in the Biotechnology industry, placing it in the top 66.9%.
Is ImmuCell's EV-to-EBITDA too high?
ImmuCell's current EV-to-EBITDA of 26.30 is near median its 10-year median of 24.91. The Biotechnology industry median EV-to-EBITDA is 14.41. ImmuCell's value of 26.30 is 82.5% above this industry median. Based on the distribution chart, ImmuCell ranks #269 out of 402 companies in the Biotechnology industry, which is below the industry midpoint. Overall, ImmuCell has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ImmuCell's EV-to-EBITDA compare to COYA and ENTX?
According to the Biotechnology industry distribution chart, ImmuCell ranks #269 out of 402 companies for EV-to-EBITDA. This places ImmuCell in the lower half of its industry. The industry median EV-to-EBITDA is 14.41. ImmuCell's value of 26.30 is 82.5% above this benchmark. While the company's 10-year median is 24.91 vs. the industry median of 14.41, ImmuCell has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 14.41, based on 402 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ImmuCell's current EV-to-EBITDA of 26.30 is 82.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on ImmuCell. For the Biotechnology industry, the median EV-to-EBITDA is 14.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ImmuCell's current EV-to-EBITDA is 26.30, which is near median its own 10-year median of 24.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ImmuCell stock overvalued right now?
Based on GuruFocus' analysis, ImmuCell (ICCC) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.91, compared to a current price of $10.13 — trading 46.6% above its estimated fair value. The current EV-to-EBITDA is 26.30, which is near median its 10-year median of 24.91 and 82.5% above the Biotechnology industry median of 14.41. ImmuCell's overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For ImmuCell (ICCC), the current EV-to-EBITDA is 26.30 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ImmuCell (ICCC) Overvalued in 2026?
Based on GuruFocus' analysis, ImmuCell stock appears to be overvalued.
The current stock price of $10.13 is trading 46.6% above its estimated GF Value™ of $6.91.
GuruFocus considers ImmuCell to be Significantly Overvalued.
Key valuation signals for ICCC:
EV-to-EBITDA: 26.30 (near median its 10-year median of 24.91)
GF Value™: $6.91 vs. price of $10.13 (46.6% above fair value)
Industry Position: 82.5% above the Biotechnology median (#269 of 402)
No single metric tells the full story. See the ICCC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.
54GF Score
Get the complete analysis for ICCC
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ICCC has been successfully added to your 
